: Rated as a top pick by Morningstar , trading roughly 7% below its fair value with a 3.62% forward yield.
: Offers a high 6.8% yield and is considered a stable defensive option under new CEO Dan Schulman. Top Value & Defensive Picks (Reliable Growth)
: Despite valuation concerns, analysts at CFRA see a 35% upside due to accelerating AI adoption and margin expansion.
If you want to evaluate a specific company yourself, professional investors typically look for: How to Pick Stocks: the Complete Guide | IG International
These are established market leaders that often perform well during economic volatility.
: This biotech firm has surged nearly 394% year-to-date following the commercial launch of its cancer drug, Anktiva, in Saudi Arabia and Europe.
